CellProthera

CellProthera develops personalized regenerative medicine therapies using a patient's own stem cells to treat severe myocardial infarction. The company utilizes an automated technology platform to produce ProtheraCytes®, which are delivered via a proprietary transendocardial catheter to restore cardiac function. Their primary focus is on late-stage clinical development for patients recovering from heart attacks.